Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive soLid maLignancies and is characterized by poor response to current therapy and a dismal survival rate. Recent evidence indicates that PDAC is associated with frequent, altered cellular signaLing pathways. We review these key pathways as well as recent investigations in the area of pancreatic cancer stem cells. Unfortunately, most phase III randomized trials of targeted therapies have not shown a survival advantage in PDAC. However, there has been extensive laboratory and cLinical research in these areas which has revealed mechanisms of resistance involved in targeting PDAC and has provided insights into the ineffectiveness of current therapies. Current investigations will hopefully provide better insights into improved therapies and understanding of ways to overcome chemoresistance in PDAC. In this article, we discuss the current research exploring altered signaLing pathways in PDAC and potential therapeutic targets.

Original languageEnglish (US)
Title of host publicationPathobiology of Human Disease
Subtitle of host publicationA Dynamic Encyclopedia of Disease Mechanisms
PublisherElsevier Inc.
Pages2265-2273
Number of pages9
ISBN (Electronic)9780123864567
ISBN (Print)9780123864574
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Therapeutics
Neoplastic Stem Cells
Research
Neoplasms

Keywords

  • Altered signaLing
  • Cancer stem cells
  • Cellular signaLing
  • Chemoresistance
  • CLinical trials
  • EGFR
  • Erlotinib
  • Gemcitabine
  • Hedgehog
  • Metastasis
  • Notch
  • Overcome resistance
  • Pancreatic cancer
  • Pancreatic ductal adenocarcinoma
  • PanIN
  • Ras
  • SignaLing pathways
  • Src
  • STAT3
  • Survival
  • Targeting
  • Therapeutic resistance
  • Transforming growth factor-β (TGF-β)
  • Wnt

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Castellanos, J., Nagathihalli, N., & Merchant, N. (2014). Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer. In Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms (pp. 2265-2273). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-386456-7.04905-4

Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer. / Castellanos, J.; Nagathihalli, Nagaraj; Merchant, Nipun.

Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Inc., 2014. p. 2265-2273.

Research output: Chapter in Book/Report/Conference proceedingChapter

Castellanos, J, Nagathihalli, N & Merchant, N 2014, Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer. in Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Inc., pp. 2265-2273. https://doi.org/10.1016/B978-0-12-386456-7.04905-4
Castellanos J, Nagathihalli N, Merchant N. Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer. In Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Inc. 2014. p. 2265-2273 https://doi.org/10.1016/B978-0-12-386456-7.04905-4
Castellanos, J. ; Nagathihalli, Nagaraj ; Merchant, Nipun. / Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer. Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Inc., 2014. pp. 2265-2273
@inbook{ff3bc8f3b3d040e097d11afc8afebcc2,
title = "Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive soLid maLignancies and is characterized by poor response to current therapy and a dismal survival rate. Recent evidence indicates that PDAC is associated with frequent, altered cellular signaLing pathways. We review these key pathways as well as recent investigations in the area of pancreatic cancer stem cells. Unfortunately, most phase III randomized trials of targeted therapies have not shown a survival advantage in PDAC. However, there has been extensive laboratory and cLinical research in these areas which has revealed mechanisms of resistance involved in targeting PDAC and has provided insights into the ineffectiveness of current therapies. Current investigations will hopefully provide better insights into improved therapies and understanding of ways to overcome chemoresistance in PDAC. In this article, we discuss the current research exploring altered signaLing pathways in PDAC and potential therapeutic targets.",
keywords = "Altered signaLing, Cancer stem cells, Cellular signaLing, Chemoresistance, CLinical trials, EGFR, Erlotinib, Gemcitabine, Hedgehog, Metastasis, Notch, Overcome resistance, Pancreatic cancer, Pancreatic ductal adenocarcinoma, PanIN, Ras, SignaLing pathways, Src, STAT3, Survival, Targeting, Therapeutic resistance, Transforming growth factor-β (TGF-β), Wnt",
author = "J. Castellanos and Nagaraj Nagathihalli and Nipun Merchant",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-386456-7.04905-4",
language = "English (US)",
isbn = "9780123864574",
pages = "2265--2273",
booktitle = "Pathobiology of Human Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer

AU - Castellanos, J.

AU - Nagathihalli, Nagaraj

AU - Merchant, Nipun

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive soLid maLignancies and is characterized by poor response to current therapy and a dismal survival rate. Recent evidence indicates that PDAC is associated with frequent, altered cellular signaLing pathways. We review these key pathways as well as recent investigations in the area of pancreatic cancer stem cells. Unfortunately, most phase III randomized trials of targeted therapies have not shown a survival advantage in PDAC. However, there has been extensive laboratory and cLinical research in these areas which has revealed mechanisms of resistance involved in targeting PDAC and has provided insights into the ineffectiveness of current therapies. Current investigations will hopefully provide better insights into improved therapies and understanding of ways to overcome chemoresistance in PDAC. In this article, we discuss the current research exploring altered signaLing pathways in PDAC and potential therapeutic targets.

AB - Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive soLid maLignancies and is characterized by poor response to current therapy and a dismal survival rate. Recent evidence indicates that PDAC is associated with frequent, altered cellular signaLing pathways. We review these key pathways as well as recent investigations in the area of pancreatic cancer stem cells. Unfortunately, most phase III randomized trials of targeted therapies have not shown a survival advantage in PDAC. However, there has been extensive laboratory and cLinical research in these areas which has revealed mechanisms of resistance involved in targeting PDAC and has provided insights into the ineffectiveness of current therapies. Current investigations will hopefully provide better insights into improved therapies and understanding of ways to overcome chemoresistance in PDAC. In this article, we discuss the current research exploring altered signaLing pathways in PDAC and potential therapeutic targets.

KW - Altered signaLing

KW - Cancer stem cells

KW - Cellular signaLing

KW - Chemoresistance

KW - CLinical trials

KW - EGFR

KW - Erlotinib

KW - Gemcitabine

KW - Hedgehog

KW - Metastasis

KW - Notch

KW - Overcome resistance

KW - Pancreatic cancer

KW - Pancreatic ductal adenocarcinoma

KW - PanIN

KW - Ras

KW - SignaLing pathways

KW - Src

KW - STAT3

KW - Survival

KW - Targeting

KW - Therapeutic resistance

KW - Transforming growth factor-β (TGF-β)

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=85043234940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043234940&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-386456-7.04905-4

DO - 10.1016/B978-0-12-386456-7.04905-4

M3 - Chapter

AN - SCOPUS:85043234940

SN - 9780123864574

SP - 2265

EP - 2273

BT - Pathobiology of Human Disease

PB - Elsevier Inc.

ER -